次优依从CPAP对阻塞性睡眠呼吸暂停症状的影响:随机双盲对照试验
本研究纳入57例中重度阻塞性睡眠呼吸暂停且治疗前日间嗜睡(ESS>10分)、CPAP依从性次优(平均每晚使用3-4小时)超过12个月的患者,随机分为假CPAP组与继续治疗CPAP组,2周后比较。假CPAP组ESS评分较继续治疗组升高2.4分(95%CI 0.6-4.2,p=0.01),治疗CPAP在ESS上优于假CPAP的后验概率为90.4%。结论认为次优依从仍带来实质获益,但不及更高依从时的获益。
要点
- 次优依从(每晚3-4小时)的中重度OSA嗜睡患者停用CPAP后ESS升高2.4分。
- 治疗CPAP在ESS上优于假CPAP的后验概率为90.4%。
- 次优依从仍有实质获益,但低于更高依从可能获得的获益。
核心结论
- 中重度OSA伴日间嗜睡患者从次优CPAP依从中仍获得实质获益,但不及依从更高时的获益。
- 更低依从水平是否适用同样结论尚待未来试验确定。
研究设计与样本
- 2周、平行、双盲、随机对照试验。
- 纳入57例中重度OSA伴治疗前ESS>10分且CPAP依从性次优≥12个月(平均每晚3-4小时)的患者,52例完成研究并纳入最终分析(每组50%)。
- 采用最小化法分配至假CPAP组或继续治疗CPAP组,并用历史先验进行贝叶斯分析计算优效后验概率。
主要发现
- 假CPAP组ESS评分较继续治疗CPAP组升高2.4分(95%CI 0.6-4.2,p=0.01)。
- 治疗CPAP优于假CPAP的后验概率:ESS为90.4%,收缩压为90.1%,舒张压为80.3%。
关键数值与推荐
- 纳入标准:中重度OSA、治疗前ESS>10分、CPAP依从性次优≥12个月(平均每晚使用3-4小时)。
- 主要比较指标为ESS评分变化,假CPAP组升高2.4分(95%CI 0.6-4.2,p=0.01)。
临床怎么用
- 对依从性次优但仍每晚使用3-4小时的中重度OSA嗜睡患者,不应轻易停用CPAP,因其仍有实质获益。
- 应继续鼓励提高依从性以获取更大获益。
局限性
- 样本量较小(57例纳入、52例分析),随访仅2周。
- 仅针对平均每晚使用3-4小时的次优依从水平,更低依从水平结论未确立。
- 研究对象以男性(79%)、白人(93%)为主,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Continuous positive airway pressure (CPAP) is currently the treatment of choice for sleepiness in patients with obstructive sleep apnoea (OSA); however, adherence is often thought to be suboptimal. We investigated the effects of suboptimal CPAP usage on objective and subjective sleepiness parameters in patients with OSA. MATERIAL AND METHODS: In this 2-week, parallel, double-blind, randomised controlled trial we enrolled moderate-to-severe OSA patients with excessive pre-treatment daytime sleepiness (Epworth sleepiness scale (ESS) score >10 points) who had suboptimal CPAP adherence over ≥12 months (mean nightly usage time 3-4 h). Patients were allocated through minimisation to either subtherapeutic CPAP ("sham CPAP") or continuation of CPAP ("therapeutic CPAP"). A Bayesian analysis with historical priors calculated the posterior probability of superiority. RESULTS: Between May, 2016 and November, 2018, 57 patients (aged 60±8 years, 79% male, 93% Caucasian) were allocated in total, and 52 who completed the study (50% in each arm) were included in the final analysis. The unadjusted ESS score increase was 2.4 points (95% CI 0.6-4.2, p=0.01) in the sham-CPAP group when compared to continuing therapeutic CPAP. The probability of superiority of therapeutic CPAP over sham CPAP was 90.4% for ESS, 90.1% for systolic blood pressure and 80.3% for diastolic blood pressure. CONCLUSIONS: Patients with moderate-to-severe OSA and daytime sleepiness are still getting a substantial benefit from suboptimal CPAP adherence, albeit not as much as they might get if they adhered more. Whether a similar statement can be made for even lower adherence levels remains to be established in future trials.
引用
- Gaisl T, Rejmer P, Thiel S, et al. Effects of suboptimal adherence of CPAP therapy on symptoms of obstructive sleep apnoea: a randomised, double-blind, controlled trial. Eur Respir J. 2020. PMID: 31862764. doi:10.1183/13993003.01526-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。